Vol. 6 No. 3 (2026)
Reimbursement Reviews

Blinatumomab

decorative image of the issue cover

Published March 16, 2026

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses blinatumomab, 38.5 mcg/vial, lyophilized powder for solution, IV infusion.
  • Indication under consideration for reimbursement: in combination with a TKI for the first-line treatment of Ph-positive ALL in adult and pediatric patients.